drugset
drugset / Trial / NCT02269644

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

NCT02269644 ↗

Phase 3 Withdrawn Durata Therapeutics Inc., an affiliate of Allergan plc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be a double-blind, randomized, multicenter trial to assess the safety and efficacy of a single 1500 mg IV dose of dalbavancin plus a single 500 mg IV dose of azithromycin in comparison to an approved antibiotic regimen of linezolid 600 mg every 12 hours for 10-14 days plus a single 500 mg IV dose of azithromycin for the treatment of Community Acquired Bacterial Pneumonia.

Timeline

Start
2015-11
Primary completion
2016-11
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalbavancin Other / unclassified 1500 mg Intravenous
Comparator Linezolid Other / unclassified 600 mg Intravenous
Background Azithromycin Small molecule 500 mg Intravenous

Indications

No indication recorded.